Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation

Koji Kawamura, Jin Hayakawa, Yu Akahoshi, Naonori Harada, Hirofumi Nakano, Kazuaki Kameda, Tomotaka Ugai, Hidenori Wada, Ryoko Yamasaki, Yuko Ishihara, Kana Sakamoto, Masahiro Ashizawa, Miki Sato, Kiriko Terasako-Saito, Shun ichi Kimura, Misato Kikuchi, Hideki Nakasone, Rie Yamazaki, Junya Kanda, Shinichi KakoAki Tanihara, Junji Nishida, Yoshinobu Kanda

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Limited data are available on prophylaxis for herpes simplex virus (HSV) and varicella zoster virus (VZV) disease following autologous hematopoietic stem cell transplantation (auto-HCT). We retrospectively reviewed the clinical charts of 105 consecutive patients who underwent their first auto-HCT at our institution between September 2007 and June 2014. Before August 2009, 30 patients received oral acyclovir at 1000 mg/day until engraftment, whereas after September 2009, 69 patients received oral acyclovir at 200 mg/day. After engraftment, acyclovir was continued at 200 mg/day at the discretion of the attending physicians in both groups. The cumulative incidence of HSV disease at 1 year after auto-HCT was 7.7 and 4.5 % in patients who received oral acyclovir at 1000 and 200 mg/day, respectively (P = 0.75). Patients were next divided into three groups according to the timing at which acyclovir prophylaxis was stopped after auto-HCT; at engraftment, between engraftment and 1 year after auto-HCT, and later than 1 year. The cumulative incidence of VZV disease was 25.8, 7.7, and 0.0 % at 1 year, respectively. This study suggests that low-dose acyclovir prophylaxis may be effective for preventing HSV and VZV disease after auto-HCT. Our findings support the recommendation of acyclovir prophylaxis within the first year after auto-HCT.

Original languageEnglish
Pages (from-to)230-237
Number of pages8
JournalInternational Journal of Hematology
Volume102
Issue number2
DOIs
Publication statusPublished - 2015 Aug 11
Externally publishedYes

Fingerprint

Human Herpesvirus 3
Acyclovir
Hematopoietic Stem Cell Transplantation
Virus Diseases
Simplexvirus
Incidence
Physicians

Keywords

  • Autologous hematopoietic stem cell transplantation
  • Herpes simplex virus
  • Low-dose acyclovir
  • Varicella zoster virus

ASJC Scopus subject areas

  • Hematology

Cite this

Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. / Kawamura, Koji; Hayakawa, Jin; Akahoshi, Yu; Harada, Naonori; Nakano, Hirofumi; Kameda, Kazuaki; Ugai, Tomotaka; Wada, Hidenori; Yamasaki, Ryoko; Ishihara, Yuko; Sakamoto, Kana; Ashizawa, Masahiro; Sato, Miki; Terasako-Saito, Kiriko; Kimura, Shun ichi; Kikuchi, Misato; Nakasone, Hideki; Yamazaki, Rie; Kanda, Junya; Kako, Shinichi; Tanihara, Aki; Nishida, Junji; Kanda, Yoshinobu.

In: International Journal of Hematology, Vol. 102, No. 2, 11.08.2015, p. 230-237.

Research output: Contribution to journalArticle

Kawamura, K, Hayakawa, J, Akahoshi, Y, Harada, N, Nakano, H, Kameda, K, Ugai, T, Wada, H, Yamasaki, R, Ishihara, Y, Sakamoto, K, Ashizawa, M, Sato, M, Terasako-Saito, K, Kimura, SI, Kikuchi, M, Nakasone, H, Yamazaki, R, Kanda, J, Kako, S, Tanihara, A, Nishida, J & Kanda, Y 2015, 'Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation', International Journal of Hematology, vol. 102, no. 2, pp. 230-237. https://doi.org/10.1007/s12185-015-1810-4
Kawamura, Koji ; Hayakawa, Jin ; Akahoshi, Yu ; Harada, Naonori ; Nakano, Hirofumi ; Kameda, Kazuaki ; Ugai, Tomotaka ; Wada, Hidenori ; Yamasaki, Ryoko ; Ishihara, Yuko ; Sakamoto, Kana ; Ashizawa, Masahiro ; Sato, Miki ; Terasako-Saito, Kiriko ; Kimura, Shun ichi ; Kikuchi, Misato ; Nakasone, Hideki ; Yamazaki, Rie ; Kanda, Junya ; Kako, Shinichi ; Tanihara, Aki ; Nishida, Junji ; Kanda, Yoshinobu. / Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. In: International Journal of Hematology. 2015 ; Vol. 102, No. 2. pp. 230-237.
@article{73c8b7652c8f43f0ab27aff739e5a644,
title = "Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation",
abstract = "Limited data are available on prophylaxis for herpes simplex virus (HSV) and varicella zoster virus (VZV) disease following autologous hematopoietic stem cell transplantation (auto-HCT). We retrospectively reviewed the clinical charts of 105 consecutive patients who underwent their first auto-HCT at our institution between September 2007 and June 2014. Before August 2009, 30 patients received oral acyclovir at 1000 mg/day until engraftment, whereas after September 2009, 69 patients received oral acyclovir at 200 mg/day. After engraftment, acyclovir was continued at 200 mg/day at the discretion of the attending physicians in both groups. The cumulative incidence of HSV disease at 1 year after auto-HCT was 7.7 and 4.5 {\%} in patients who received oral acyclovir at 1000 and 200 mg/day, respectively (P = 0.75). Patients were next divided into three groups according to the timing at which acyclovir prophylaxis was stopped after auto-HCT; at engraftment, between engraftment and 1 year after auto-HCT, and later than 1 year. The cumulative incidence of VZV disease was 25.8, 7.7, and 0.0 {\%} at 1 year, respectively. This study suggests that low-dose acyclovir prophylaxis may be effective for preventing HSV and VZV disease after auto-HCT. Our findings support the recommendation of acyclovir prophylaxis within the first year after auto-HCT.",
keywords = "Autologous hematopoietic stem cell transplantation, Herpes simplex virus, Low-dose acyclovir, Varicella zoster virus",
author = "Koji Kawamura and Jin Hayakawa and Yu Akahoshi and Naonori Harada and Hirofumi Nakano and Kazuaki Kameda and Tomotaka Ugai and Hidenori Wada and Ryoko Yamasaki and Yuko Ishihara and Kana Sakamoto and Masahiro Ashizawa and Miki Sato and Kiriko Terasako-Saito and Kimura, {Shun ichi} and Misato Kikuchi and Hideki Nakasone and Rie Yamazaki and Junya Kanda and Shinichi Kako and Aki Tanihara and Junji Nishida and Yoshinobu Kanda",
year = "2015",
month = "8",
day = "11",
doi = "10.1007/s12185-015-1810-4",
language = "English",
volume = "102",
pages = "230--237",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation

AU - Kawamura, Koji

AU - Hayakawa, Jin

AU - Akahoshi, Yu

AU - Harada, Naonori

AU - Nakano, Hirofumi

AU - Kameda, Kazuaki

AU - Ugai, Tomotaka

AU - Wada, Hidenori

AU - Yamasaki, Ryoko

AU - Ishihara, Yuko

AU - Sakamoto, Kana

AU - Ashizawa, Masahiro

AU - Sato, Miki

AU - Terasako-Saito, Kiriko

AU - Kimura, Shun ichi

AU - Kikuchi, Misato

AU - Nakasone, Hideki

AU - Yamazaki, Rie

AU - Kanda, Junya

AU - Kako, Shinichi

AU - Tanihara, Aki

AU - Nishida, Junji

AU - Kanda, Yoshinobu

PY - 2015/8/11

Y1 - 2015/8/11

N2 - Limited data are available on prophylaxis for herpes simplex virus (HSV) and varicella zoster virus (VZV) disease following autologous hematopoietic stem cell transplantation (auto-HCT). We retrospectively reviewed the clinical charts of 105 consecutive patients who underwent their first auto-HCT at our institution between September 2007 and June 2014. Before August 2009, 30 patients received oral acyclovir at 1000 mg/day until engraftment, whereas after September 2009, 69 patients received oral acyclovir at 200 mg/day. After engraftment, acyclovir was continued at 200 mg/day at the discretion of the attending physicians in both groups. The cumulative incidence of HSV disease at 1 year after auto-HCT was 7.7 and 4.5 % in patients who received oral acyclovir at 1000 and 200 mg/day, respectively (P = 0.75). Patients were next divided into three groups according to the timing at which acyclovir prophylaxis was stopped after auto-HCT; at engraftment, between engraftment and 1 year after auto-HCT, and later than 1 year. The cumulative incidence of VZV disease was 25.8, 7.7, and 0.0 % at 1 year, respectively. This study suggests that low-dose acyclovir prophylaxis may be effective for preventing HSV and VZV disease after auto-HCT. Our findings support the recommendation of acyclovir prophylaxis within the first year after auto-HCT.

AB - Limited data are available on prophylaxis for herpes simplex virus (HSV) and varicella zoster virus (VZV) disease following autologous hematopoietic stem cell transplantation (auto-HCT). We retrospectively reviewed the clinical charts of 105 consecutive patients who underwent their first auto-HCT at our institution between September 2007 and June 2014. Before August 2009, 30 patients received oral acyclovir at 1000 mg/day until engraftment, whereas after September 2009, 69 patients received oral acyclovir at 200 mg/day. After engraftment, acyclovir was continued at 200 mg/day at the discretion of the attending physicians in both groups. The cumulative incidence of HSV disease at 1 year after auto-HCT was 7.7 and 4.5 % in patients who received oral acyclovir at 1000 and 200 mg/day, respectively (P = 0.75). Patients were next divided into three groups according to the timing at which acyclovir prophylaxis was stopped after auto-HCT; at engraftment, between engraftment and 1 year after auto-HCT, and later than 1 year. The cumulative incidence of VZV disease was 25.8, 7.7, and 0.0 % at 1 year, respectively. This study suggests that low-dose acyclovir prophylaxis may be effective for preventing HSV and VZV disease after auto-HCT. Our findings support the recommendation of acyclovir prophylaxis within the first year after auto-HCT.

KW - Autologous hematopoietic stem cell transplantation

KW - Herpes simplex virus

KW - Low-dose acyclovir

KW - Varicella zoster virus

UR - http://www.scopus.com/inward/record.url?scp=84939000383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939000383&partnerID=8YFLogxK

U2 - 10.1007/s12185-015-1810-4

DO - 10.1007/s12185-015-1810-4

M3 - Article

C2 - 25990803

AN - SCOPUS:84939000383

VL - 102

SP - 230

EP - 237

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -